Skip to main content

Table 4 Seroprotection and seroconversion

From: Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study

 

All patients

(n = 226)

% (na/Nb)

bDMARDs monotherapy

(n = 80)

% (na/Nb)

bDMARDs + DMARDs

(n = 110)

% (na/Nb)

Rituximab

(n = 5)

% (na/Nb)

Systemic disorders (except Rituximab)

(n = 18)

% (na/Nb)

Other

(n = 13)

% (na/Nb)

Controls

(n = 15)

% (na/Nb)

A/Cal H1N1pdm09

 Seroprotection

  Pre-vaccine 40

97.0 (196/202)

97.2 (70/72)

96.9 (94/97)

100 (4/4)

100 (17/17)

91.7 (11/12)

100 (11/11)

  Post-vaccine 40

98.9 (196/198)

100 (66/66)

98.9 (98/99)

100 (5/5)

100 (17/17)

90.9 (10/11)

100 (13/13)

  p-valuec

0.10

-

0.16

-

-

1.0

-

  Pre-vaccine 110

43.6 (88/202)

54.2 (39/72)

35.1 (34/97)

50.0 (2/4)

47.1 (8/17)

41.7 (5/12)

72.7 (8/11)

  Post-vaccine 110

65.2 (129/198)

63.6 (42/66)

66.7 (66/99)

40.0 (2/5)

58.8 (10/17)

81.8 (9/11)

84.6 (11/13)

  p-valuec

< 0.0001*

0.05

< 0.0001*

-

0.16

0.01

0.16

 Seroconversion

21.8 (38/174)

13.8 (8/58)

27.9 (24/86)

0 (0/4)

12.5 (2/16)

40.0 (4/10)

33.3 (3/9)

A/Swi H3N2

 Seroprotection

  Pre-vaccine 40

93.1 (188/202)

93.1 (67/72)

93.8 (91/97)

100 (4/4)

82.4 (14/17)

100 (12/12)

90.9 (10/11)

  Post-vaccine 40

97.5 (193/198)

98.5 (65/66)

96.9 (96/99)

100 (5/5)

94.1 (16/17)

100 (11/11)

100 (13/13)

  p-valuec

0.0016*

0.045

0.045

-

0.16

-

-

  Pre-vaccine 110

14.9 (30/202)

15.3 (11/72)

13.4 (13/97)

25.0 (1/4)

11.8 (2/17)

25.0 (3/12)

18.2 (2/11)

  Post-vaccine 110

31.3 (62/198)

34.9 (23/66)

28.3 (28/99)

40.0 (2/5)

29.4 (5/17)

36.4 (4/11)

84.6 (11/13)

  p-valuec

< 0.0001*

0.006*

0.0002*

-

0.16

0.16

0.01

 Seroconversion

18.4 (32/174)

15.5 (9/58)

19.8 (17/86)

25.0 (1/4)

18.8 (3/16)

20.0 (2/10)

66.7 (6/9)

B/Phu Yamagata

 Seroprotection

  Pre-vaccine 40

97.0 (196/202)

95.8 (69/72)

97.9 (95/97)

75.0 (3/4)

100 (17/17)

100 (12/12)

100 (11/11)

  Post-vaccine 40

100 (198/198)

100 (66/66)

100 (99/99)

100 (5/5)

100 (17/17)

100 (11/11)

100 (13/13)

  p-valuec

-

-

-

-

-

-

-

  Pre-vaccine 110

17.8 (36/202)

18.1 (13/72)

14.4 (14/97)

50.0 (2/4)

29.4 (5/17)

16.7 (2/12)

18.2 (2/11)

  Post-vaccine 110

19.7 (39/198)

15.2 (10/66)

17.2 (17/99)

40.0 (2/5)

35.3 (6/17)

36.4 (4/11)

53.9 (7/13)

  p-valuec

0.35

0.71

0.26

0.32

0.16

0.32

0.045

 Seroconversion

6.9 (12/174)

5.2 (3/58)

5.8 (5/86)

50.0 (2/4)

6.3 (1/16)

10.0 (1/10)

22.2 (29)

  1. Abbreviations: DMARDs disease modifying antirheumatic drugs; bDMARDs biological DMARDs
  2. aFor seroprotection, number of patients with antibody level above threshold. For seroconversion, number fulfilling the criteria for seroconversion. bTotal number of patients with available blood sample
  3. cThe proportion of children increasing to a protective level of antibodies was analysed using McNemars test. Only children with both pre-vaccine and post-vaccine blood samples were included in the analyses. The calculation of the p-value was not possible when one of the proportions was 100 %
  4. *Only p-values < 0.007 = 0.05/7 were considered statistically significant after Bonferroni correction for multiple testing for each outcome and each cut off
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096